Jane L Liesveld

US Patent:

20060183223, Aug 17, 2006

Filed:

Jan 20, 2006

Appl. No.:

11/335573

Inventors:

Michael King - Rochester NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John Gentile - Rochester NY, US
Nathan Clark - Rochester NY, US
Nipa Mody - West Henrietta NY, US

International Classification:

C12N 5/08

US Classification:

435372000

Abstract:

The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.

US Patent:

20070031406, Feb 8, 2007

Filed:

Oct 22, 2004

Appl. No.:

10/576428

Inventors:

Martin Zand - Rochester NY, US
Jainulabdeen Ifthikharuddin - Rochester NY, US
Jane Liesveld - Rochester NY, US
Camille Abboud - Rochester NY, US

International Classification:

A61K 39/395

US Classification:

424144100, 424155100

Abstract:

Methods and products are described for inducing B cell apoptosis, using antibody-induced apoptosis. Specifically, polyclonal antiserum or one or more monoclonal antibodies, either alone or in combination, as well as fragments or variants thereof are employed in the methods and products of the present invention. These antibodies, or fragments or variants thereof, are capable of binding to B cell surface markers under conditions effective to collectively or individually induce apoptosis of the contacted B cell. Consequently, the methods and products of the present invention can be used therapeutically to treat, or as a preventative agent to protect against, a B cell-related condition or disorder.

US Patent:

20070178084, Aug 2, 2007

Filed:

Dec 4, 2006

Appl. No.:

11/607879

Inventors:

Michael King - Rochester NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John Gentile - Spencerport NY, US
Kuldeepsinh Rana - Rochester NY, US
Nathan Clark - Rochester NY, US
Nipa Mody - West Henrietta NY, US

International Classification:

A61K 39/395
G01N 33/567
G01N 33/574

US Classification:

424140100, 435007210, 435007230

Abstract:

The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.

US Patent:

20090022768, Jan 22, 2009

Filed:

Jan 16, 2008

Appl. No.:

12/007877

Inventors:

Michael R. King - Rochester NY, US
Jane Liesveld - Rochester NY, US
Kuldeepsinh Rana - Rochester NY, US

International Classification:

A61K 9/00
C12M 1/00
C12N 5/00
A61P 35/00

US Classification:

424422, 4352831, 4353061, 435375

Abstract:

The present invention relates to methods and apparatuses for neutralizing cancer cells. In particular, the invention relates to separating of cancer cell type from a mixture of different cell types based on the differential rolling property of cancer cell on a substrate coated with a first molecules that exhibits adhesive property with the particular cell type and neutralizing the cancer cell by a second molecule that is also coated on the substrate. This technology is adaptable for use in vivo, in vitro, or ex vivo tumor neutralization.

US Patent:

20090253204, Oct 8, 2009

Filed:

Oct 17, 2008

Appl. No.:

12/289006

Inventors:

Michael R. King - Rochester NY, US
Nichola Charles - Rochester NY, US
Jane Liesveld - Rochester NY, US
John P. Gentile - Spencerport NY, US
Nathan Clark - Rochester NY, US
Nipa A. Mody - West Henrietta NY, US

Assignee:

University of Rochester - Rochester NY

International Classification:

C12N 5/06

US Classification:

435395

Abstract:

The present invention relates to methods and apparatuses for cell separation. In particular, the invention relates to separation of a particular cell type from a mixture of different cell types based on the differential rolling property of the particular cell type on a substrate coated with molecules that exhibits adhesive property with the particular cell type. This technology is adaptable for use in implantable shunts and devices for cell trafficking or tumor neutralization.

US Patent:

20140047572, Feb 13, 2014

Filed:

Mar 15, 2013

Appl. No.:

13/838111

Inventors:

Yuhchyau CHEN - Pittsford NY, US
Jane L. LIESVELD - Rochester NY, US
Lin GAN - Pittsford NY, US

Assignee:

University of Rochester - Rochester NY

International Classification:

A61K 31/4152
G01N 33/50
A61K 45/06

US Classification:

800 18, 514404, 424 937, 435355, 435 721

Abstract:

Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal. The chimeric thrombopoietin receptor comprises either the transmembrane domain of a human thrombopoietin receptor or both the extracellular and transmembrane domains of a human thrombopoietin receptor operably coupled to a cytoplasmic domain of a non-human thrombopoietin receptor.

US Patent:

20140234322, Aug 21, 2014

Filed:

May 2, 2014

Appl. No.:

14/268126

Inventors:

Yuhchyau CHEN - Pittsford NY, US
Jane L. LIESVELD - Rochester NY, US

Assignee:

UNIVERSITY OF ROCHESTER - Rochester NY

International Classification:

A61K 31/4152
A61K 45/06
A61K 38/19
C07K 16/28
A61K 39/395

US Classification:

4241391, 514404, 514 78

Abstract:

Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal. The chimeric thrombopoietin receptor comprises either the transmembrane domain of a human thrombopoietin receptor or both the extracellular and transmembrane domains of a human thrombopoietin receptor operably coupled to a cytoplasmic domain of a non-human thrombopoietin receptor.